BioSpace News Archive

MAIA Biotechnology, Inc., (NYSE: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the full year ended December 31, 2022, and provided a corporate update.

In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced a collaboration with Novartis Pharmaceuticals Corporation (Novartis) to increase awareness for Lipoprotein(a) (Lp(a)). High levels of Lp(a) are associated with increased risk of heart attack, stroke and other life threatening conditions.

atai reported fourth quarter and full year 2022 financial results and provided clinical pipeline highlights.

PTC Therapeutics, Inc. (NASDAQ: PTCT ). Stuart Peltz , Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years.

Leap Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2022.

ProfoundBio will present two posters from its lead program, PRO1184, a folate receptor alpha (FRα)-directed exatecan-based antibody-drug conjugate (ADC) with a novel hydrophilic linker, at the American Association for Cancer Research (AACR) Annual Meeting being held April 14 – 19, 2023.

INVO Bioscience, Inc. today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor to purchase 3,680,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

Spectral Medical Inc. today announced its financial results for the fourth quarter and for the year ended December 31, 2022 and provided a corporate update.

Biocept, Inc. announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide (NCT05414123).

SQI Diagnostics Inc. announces that certain insiders of the Company, who are also control persons of the Company and collectively own, or exercise control or direction over, an aggregate of 75% of the issued and outstanding common shares.